UCL Discovery Stage
UCL home » Library Services » Electronic resources » UCL Discovery Stage

Association of Mineralocorticoid Receptor Antagonists With the Mortality and Cardiovascular Effects in Dialysis Patients: A Meta-analysis

Gou, WJ; Zhou, FW; Providencia, R; Wang, B; Zhang, H; Hu, SL; Gao, XL; ... Li, T; + view all (2022) Association of Mineralocorticoid Receptor Antagonists With the Mortality and Cardiovascular Effects in Dialysis Patients: A Meta-analysis. Frontiers in Pharmacology , 13 , Article 823530. 10.3389/fphar.2022.823530. Green open access

[thumbnail of fphar-13-823530.pdf]
Preview
Text
fphar-13-823530.pdf - Published Version

Download (1MB) | Preview

Abstract

Whether Mineralocorticoid receptor antagonists (MRA) reduce mortality and cardiovascular effects of dialysis patients remains unclear. A meta-analysis was designed to investigate whether MRA reduce mortality and cardiovascular effects of dialysis patients, with a registration in INPLASY (INPLASY2020120143). The meta-analysis revealed that MRA significantly reduced all-cause mortality (ACM) and cardiovascular mortality (CVM). Patients receiving MRA presented improved left ventricular mass index (LVMI) and left ventricular ejection fraction (LVEF), decreased systolic blood pressure (SBP) and diastolic blood pressure (DBP). There was no significant difference in the serum potassium level between the MRA group and the placebo group. MRA vs. control exerts definite survival and cardiovascular benefits in dialysis patients, including reducing all-cause mortality and cardiovascular mortality, LVMI, and arterial blood pressure, and improving LVEF. In terms of safety, MRA did not increase serum potassium levels for dialysis patients with safety. Systematic Review Registration: (https://inplasy.com/inplasy-protocol-1239-2/), identifier (INPLASY2020120143).

Type: Article
Title: Association of Mineralocorticoid Receptor Antagonists With the Mortality and Cardiovascular Effects in Dialysis Patients: A Meta-analysis
Open access status: An open access version is available from UCL Discovery
DOI: 10.3389/fphar.2022.823530
Publisher version: https://doi.org/10.3389/fphar.2022.823530
Language: English
Additional information: © 2022 Gou, Zhou, Providencia, Wang, Zhang, Hu, Gao, Tuo, Zhang and Li. This is an open-access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/).
Keywords: hemodialysis, mineralocorticoid receptor antagonists, mortality, end-stage renal disease, cardiovascular mortaility
UCL classification: UCL
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Population Health Sciences > Institute of Health Informatics
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences
URI: https://discovery-pp.ucl.ac.uk/id/eprint/10157399
Downloads since deposit
540Downloads
Download activity - last month
Download activity - last 12 months
Downloads by country - last 12 months

Archive Staff Only

View Item View Item